Bristol Myers Squibb’s rheumatoid arthritis drug Orencia won marketing clearance as the first medicine approved for the prevention of moderate-to-severe acute graft versus host disease (aGvHD) in patients 2 years of age and older who have received unrelated donor hematopoietic stem cell transplantation.
Sanofi is investing more into its transplant operations through a $1.9 billion merger deal with Kadmon Holdings, another biopharma company that develops therapies for diseases with large unmet medical needs.
The U.S. Food and Drug Administration approved Rezurock (belumosudil) as a new treatment option for anyone over 12 years of age with chronic graft-versus-host disease after two prior lines of therapy have failed.
Wilmington, Delaware-based Incyte Corporation announced data from the Phase III REACH3 trial of Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).
Incyte announced that data from the Phase 3 REACH2 study were published in The New England Journal of Medicine demonstrating that ruxolitinib – marketed in the United States as Jakafi – improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GVHD) compared to best available therapy.
Incyte Corporation’s pivotal Phase III GRAVITAS-301 trial of itacitinib in combination with corticosteroids in treatment-naïve acute graft-versus-host disease (GVHD) did not hit the primary endpoint, sending company shares down almost 10 percent.
Novartis announced positive topline results from the Phase III REACH2 study evaluating Jakavi (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease.
The U.S. Food and Drug Administration approved Incyte Corp.’s Jakafi as the first treatment for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.